Trial Profile
An Open-Label, Parallel-Group Study to Evaluate the Pharmacokinetics of Lemborexant (E2006) and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared to Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 21 Jan 2020
Price :
$35
*
At a glance
- Drugs Lemborexant (Primary)
- Indications Circadian rhythm sleep disorders; Insomnia; Sleep apnoea syndrome
- Focus Pharmacokinetics
- Sponsors Eisai Inc
- 16 Mar 2019 Results presented at the 120th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
- 05 Sep 2018 Status changed from recruiting to completed.
- 26 Feb 2018 New trial record